HemaCare Corporation is a leading provider of apheresis products, human blood cells, and apheresis collection services, with over 30 years of experience. HemaCare supplies human-derived blood components for preclinical and clinical applications in biologics, immunotherapy, cell therapy, assay development, and medical devices.
Human cells and tissue are critical raw material for cell therapy, tissue-engineered, and ex vivo gene therapy products. Quality of this cellular raw material is a major determinant of final product characteristics, but is complicated by inherent heterogeneity and inter-individual variability of living biologics. Inconsistent collection procedures amplify this variability, adversely affecting the manufacturing process from the outset. Controlled, consistent cell collection minimizes variability, and enables successful manufacturing.
HemaCare’s core competency is apheresis collection. HemaCare has addressed the need for optimized cell collection with a program for controlling and qualifying its apheresis procedures and collection sites, to supply human-derived blood components for development and qualification of novel biologics, immunotherapy, cell and gene therapies, assays, and medical devices.
Specialties
Peripheral Blood Mononuclear Cells (PBMC), Whole Blood & Samples, Customized- Protocol Specific Apheresis Collections, cGMP / cGTP Facility, Apheresis, Stem Cells, Healthy Donor, Cellular Therapy
